We propose that fibulin-3, as well as other pericellular ECM proteins, can be inhibited to reduce immunosuppression in GBM and should be explored as adjuvant targets for successful immunotherapy of these aggressive brain tumors. This evidence concerns the gene EFEMP1 and glioblastoma.